Volume | 2 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ARCA Biopharma Inc | ABIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.48 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 2 | - | 1.56 - 3.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:59:49 | 2 | $ 3.40 | USD |
ARCA Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
50.46M | 14.50M | - | 0 | -5.34M | -0.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ARCA Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.24 | 3.75 | 3.21 | 3.46 | 316,318 | 0.24 | 7.41% |
1 Month | 1.78 | 3.88 | 1.6901 | 3.24 | 4,645,271 | 1.70 | 95.51% |
3 Months | 1.57 | 3.88 | 1.57 | 3.23 | 1,539,105 | 1.91 | 121.66% |
6 Months | 1.97 | 3.88 | 1.56 | 3.20 | 727,573 | 1.51 | 76.65% |
1 Year | 1.96 | 3.88 | 1.56 | 3.16 | 372,990 | 1.52 | 77.55% |
3 Years | 3.51 | 3.90 | 1.56 | 2.97 | 228,493 | -0.03 | -0.85% |
5 Years | 5.43 | 22.00 | 1.56 | 7.32 | 395,915 | -1.95 | -35.91% |
ARCA Biopharma Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |